Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.

Hendrikx T, Watzenböck ML, Walenbergh SM, Amir S, Gruber S, Kozma MO, Grabsch HI, Koek GH, Pierik MJ, Staufer K, Trauner M, Kalhan SC, Jonkers D, Hofker MH, Binder CJ, Shiri-Sverdlov R.

BMC Med. 2016 Jul 22;14(1):107. doi: 10.1186/s12916-016-0652-0.

2.

2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis.

Ley K.

Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):429-38. doi: 10.1161/ATVBAHA.115.306009.

PMID:
26821946
3.

Beyond vascular inflammation--recent advances in understanding atherosclerosis.

Wolf D, Zirlik A, Ley K.

Cell Mol Life Sci. 2015 Oct;72(20):3853-69. doi: 10.1007/s00018-015-1971-6. Review.

4.

Vaccination to modulate atherosclerosis.

Kimura T, Tse K, Sette A, Ley K.

Autoimmunity. 2015 May;48(3):152-60. doi: 10.3109/08916934.2014.1003641. Review.

5.

Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine.

Gonen A, Hansen LF, Turner WW, Montano EN, Que X, Rafia A, Chou MY, Wiesner P, Tsiantoulas D, Corr M, VanNieuwenhze MS, Tsimikas S, Binder CJ, Witztum JL, Hartvigsen K.

J Lipid Res. 2014 Oct;55(10):2137-55. doi: 10.1194/jlr.M053256.

6.

Scavenger receptor function of mouse Fcγ receptor III contributes to progression of atherosclerosis in apolipoprotein E hyperlipidemic mice.

Zhu X, Ng HP, Lai YC, Craigo JK, Nagilla PS, Raghani P, Nagarajan S.

J Immunol. 2014 Sep 1;193(5):2483-95. doi: 10.4049/jimmunol.1303075.

7.

Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects.

Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV.

Front Physiol. 2014 May 27;5:196. doi: 10.3389/fphys.2014.00196. Review.

8.

B cells and humoral immunity in atherosclerosis.

Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ.

Circ Res. 2014 May 23;114(11):1743-56. doi: 10.1161/CIRCRESAHA.113.301145. Review.

9.

Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Chyu KY, Shah PK.

Ther Adv Vaccines. 2014 Mar;2(2):56-66. doi: 10.1177/2051013613514327. Review.

10.

Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100.

Tse K, Gonen A, Sidney J, Ouyang H, Witztum JL, Sette A, Tse H, Ley K.

Front Immunol. 2013 Dec 27;4:493. doi: 10.3389/fimmu.2013.00493.

11.

Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts.

Kummu O, Turunen SP, Prus P, Lehtimäki J, Veneskoski M, Wang C, Hörkkö S.

Immunology. 2014 Mar;141(3):416-30. doi: 10.1111/imm.12204.

12.

Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation.

Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, Harmon DB, Tsimikas S, Witztum JL, Bender TP, McNamara CA.

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2771-9. doi: 10.1161/ATVBAHA.113.302571.

13.

The role of the vascular dendritic cell network in atherosclerosis.

Alberts-Grill N, Denning TL, Rezvan A, Jo H.

Am J Physiol Cell Physiol. 2013 Jul 1;305(1):C1-21. doi: 10.1152/ajpcell.00017.2013. Review.

14.

B cell subsets in atherosclerosis.

Perry HM, Bender TP, McNamara CA.

Front Immunol. 2012 Dec 11;3:373. doi: 10.3389/fimmu.2012.00373.

15.

Scavenger receptors target glycolipids for natural killer T cell activation.

Freigang S, Landais E, Zadorozhny V, Kain L, Yoshida K, Liu Y, Deng S, Palinski W, Savage PB, Bendelac A, Teyton L.

J Clin Invest. 2012 Nov;122(11):3943-54. doi: 10.1172/JCI62267.

16.

Maternal immunization affects in utero programming of insulin resistance and type 2 diabetes.

Eberle C, Merki E, Yamashita T, Johnson S, Armando AM, Quehenberger O, Napoli C, Palinski W.

PLoS One. 2012;7(9):e45361. doi: 10.1371/journal.pone.0045361.

17.

Emerging applications for zebrafish as a model organism to study oxidative mechanisms and their roles in inflammation and vascular accumulation of oxidized lipids.

Fang L, Miller YI.

Free Radic Biol Med. 2012 Oct 1;53(7):1411-20. doi: 10.1016/j.freeradbiomed.2012.08.004. Review.

18.

Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.

Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E, Wagner O, Tsimikas S, Witztum JL, Binder CJ.

J Lipid Res. 2012 Jul;53(7):1316-26. doi: 10.1194/jlr.M025445.

19.

Recognition of Porphyromonas gingivalis gingipain epitopes by natural IgM binding to malondialdehyde modified low-density lipoprotein.

Turunen SP, Kummu O, Harila K, Veneskoski M, Soliymani R, Baumann M, Pussinen PJ, Hörkkö S.

PLoS One. 2012;7(4):e34910. doi: 10.1371/journal.pone.0034910.

20.

CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide.

Chyu KY, Zhao X, Dimayuga PC, Zhou J, Li X, Yano J, Lio WM, Chan LF, Kirzner J, Trinidad P, Cercek B, Shah PK.

PLoS One. 2012;7(2):e30780. doi: 10.1371/journal.pone.0030780.

Items per page

Supplemental Content

Support Center